Table 2.

Representative small molecules targeting protein degradation under clinical evaluation

Small molecules	Target	Application	Stage of development	Refs.
KSQ-4279	USP1	Patients with advanced solid tumors alone or in combination with an oral PARPi	Phase I	NCT05240898
Perifosine	UCHL3	Refractory tumors	Phase I or II	NCT00873457, NCT01049841, NCT00391560, NCT01097018, NCT00054145
VLX1570	UCHL and USP14	Multiple myeloma	Phase II	NCT02372240
AMG-232	MDM2	Treating patients with acute myeloid leukemia that has come back (recurrent), does not respond to treatment (refractory), or is newly diagnosed in combination with decitabine	Phase I	NCT03041688
ALRN-6924	MDM2/MDMX	Treatment for resistant (refractory) pediatric cancer	Phase I	NCT03654716
DS-3032b	MDM2	Treatment of relapsed and/or refractory multiple myeloma	Phase I	NCT02579824
RO6839921	MDM2	Patients with advanced cancers	Phase I	NCT02098967, NCT01462175
BI 907828	MDM2	Different types of advanced cancer	Phase I	NCT03449381, NCT05376800, NCT03964233
NX-1607	Cbl-b	Advanced malignancies	Phase I	NCT05107674
KPG-818	CRL4	Hematological malignancies	Phase I	NCT04283097